United Asset Strategies Inc. Has $14.29 Million Stake in Cigna Group $CI

United Asset Strategies Inc. lowered its holdings in shares of Cigna Group (NYSE:CI) by 9.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,237 shares of the health services provider’s stock after selling 4,495 shares during the quarter. Cigna Group accounts for about 1.2% of United Asset Strategies Inc.’s portfolio, making the stock its 23rd biggest position. United Asset Strategies Inc.’s holdings in Cigna Group were worth $14,293,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Valeo Financial Advisors LLC boosted its holdings in shares of Cigna Group by 86,071.1% in the second quarter. Valeo Financial Advisors LLC now owns 3,475,282 shares of the health services provider’s stock valued at $1,148,859,000 after buying an additional 3,471,249 shares during the period. Nuveen LLC acquired a new position in Cigna Group in the 1st quarter worth $727,905,000. Price T Rowe Associates Inc. MD increased its holdings in Cigna Group by 10.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,056,806 shares of the health services provider’s stock worth $3,966,690,000 after purchasing an additional 1,094,327 shares in the last quarter. GQG Partners LLC lifted its holdings in shares of Cigna Group by 21.5% in the first quarter. GQG Partners LLC now owns 4,886,674 shares of the health services provider’s stock valued at $1,607,716,000 after purchasing an additional 865,092 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Cigna Group by 38.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,649,837 shares of the health services provider’s stock valued at $542,796,000 after purchasing an additional 457,052 shares in the last quarter. 86.99% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Wolfe Research dropped their target price on Cigna Group from $345.00 to $325.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 15th. Truist Financial lowered their price objective on shares of Cigna Group from $375.00 to $310.00 in a report on Friday, October 31st. JPMorgan Chase & Co. reduced their target price on shares of Cigna Group from $428.00 to $375.00 and set an “overweight” rating for the company in a report on Tuesday, November 4th. The Goldman Sachs Group lowered their price target on shares of Cigna Group from $370.00 to $330.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. Finally, Cantor Fitzgerald decreased their price objective on Cigna Group from $365.00 to $325.00 in a report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Cigna Group presently has an average rating of “Moderate Buy” and an average price target of $339.73.

Cigna Group Stock Up 3.7%

Shares of CI stock opened at $267.82 on Wednesday. Cigna Group has a 52-week low of $239.51 and a 52-week high of $350.00. The stock has a market cap of $71.54 billion, a price-to-earnings ratio of 14.62, a PEG ratio of 0.88 and a beta of 0.44. The firm’s 50-day moving average is $291.71 and its 200-day moving average is $302.28. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.71 and a current ratio of 0.71.

Cigna Group (NYSE:CI) last posted its quarterly earnings results on Thursday, October 30th. The health services provider reported $7.83 EPS for the quarter, topping analysts’ consensus estimates of $7.64 by $0.19. The business had revenue of $69.57 billion during the quarter, compared to analysts’ expectations of $66.40 billion. Cigna Group had a return on equity of 18.80% and a net margin of 1.92%.Cigna Group’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the company posted $7.51 earnings per share. Cigna Group has set its FY 2025 guidance at 29.600- EPS. Sell-side analysts predict that Cigna Group will post 29.77 EPS for the current year.

Cigna Group Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Thursday, December 4th will be issued a dividend of $1.51 per share. The ex-dividend date of this dividend is Thursday, December 4th. This represents a $6.04 dividend on an annualized basis and a dividend yield of 2.3%. Cigna Group’s payout ratio is presently 26.64%.

Insider Buying and Selling at Cigna Group

In related news, CEO David Cordani bought 4,134 shares of Cigna Group stock in a transaction that occurred on Monday, November 3rd. The stock was acquired at an average price of $241.88 per share, with a total value of $999,931.92. Following the acquisition, the chief executive officer owned 157,935 shares of the company’s stock, valued at approximately $38,201,317.80. This represents a 2.69% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Nicole S. Jones sold 28,526 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $300.00, for a total transaction of $8,557,800.00. Following the completion of the transaction, the insider directly owned 25,648 shares in the company, valued at approximately $7,694,400. This represents a 52.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.70% of the company’s stock.

About Cigna Group

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.